Ebola: Commitment to Developing Medical Advances

About PhRMA

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are laser focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. Over the last decade, PhRMA member companies have invested more than $850 billion in the search for new treatments and cures, and they support nearly five million jobs in the United States.

Connect with PhRMA

For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.VotersforCures.org
www.AmericasMedicines.com
www.Facebook.com/PhRMA
www.X.com/PhRMA

To download the full report, click here.

Researchers around the world, from both the public and private sectors, are increasingly working collaboratively to develop new ways to prevent the spread of Ebola and treat patients who have contracted the virus. The research and development process for new medicines is a lengthy, challenging and complex process, which is more often than not fraught with scientific setbacks. On average it takes 10-15 years and $2.6 billion to develop a new medicine. Biopharmaceutical researchers are working to compress that timeline for Ebola projects in their pipelines.

Ebola: Commitment to Developing Medical Advances image

Report

Research and Development